Research progress of tenofovir alafenamide in blocking mother-to-child transmission of hepatitis B virus
10.12092/j.issn.1009-2501.2023.05.013
- Author:
Linling QI
1
;
Shourong LIU
2
Author Information
1. Zhejiang Chinese Medical University
2. Department of Hepatology, Affiliated Hangzhou Xixi Hospital, Zhejiang University School of Medicine
- Publication Type:Journal Article
- Keywords:
blocking of mother-to-child transmission;
hepatitis B;
tenofovir alafenamide
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2023;28(5):578-582
- CountryChina
- Language:Chinese
-
Abstract:
Hepatitis B virus (HBV) infection is a global public health problem, and the prevention of mother-to-child transmission (MTCT) is an important intervention method. As a new nucleoside reverse transcriptase inhibitor, tenofovir alafenamide (TAF) has the characteristics of strong liver targeting and low peripheral blood exposure. Although it has been used in the treatment of chronic hepatitis B widely, its application in blocking mother-to-child transmission of HBV is still limited. This paper reviews the characteristics of TAF, the effects of TAF on infants and pregnant women, in order to provide new ideas for the prevention of mother-to-child transmission of HBV.
